Effects of hydralazine on pregnant rats and their fetuses

Abstract

Objective: We conducted this study to assess potential teratogenic or fetotoxic effects of in utero hydralazine exposure in the rat.

Study design: Pregnant rats were treated with hydralazine (0, 15, or 30 mg/kg/day) by either gavage or subcutaneous injection during gestation days 8 through 19, inclusively. Surviving animals were killed, uterine contents examined, and fetuses evaluated by Wilson's method for teratologic examination.

Results: Oral administration did not affect maternal weight gain or fetal or placental weights. Subcutaneous administration decreased fetal and placental weights but only in dams given the highest dose subcutaneously; significantly increased maternal mortality and reduced maternal weight gain were also observed. There was no increased incidence of fetal anomalies in any group.

Conclusion: Hydralazine does not have teratogenic or fetopathic effects when given to rats in dosages that are nontoxic to the mother.